RxDoctor Payments Data

Nona Ahankoob, MD

Internal Medicine · Porter Ranch, CANPI 1790078228

Payments from drug & device makers

$849in general payments, 2019–2025

Across 44 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$280
  • Lilly USA, LLC$185
  • Novo Nordisk$143
  • Amarin Pharma, Inc.$40
  • Dexcom, Inc.$39
  • Regeneron Healthcare Solutions, Inc.$35
  • plus $127 from 7 others

What the payments were for

  • Travel & lodging$51%
  • Food & beverage$84499%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$849 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$944
Medicare patients
18
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$49,133
MounjaroTirzepatide30$34,175
Diclofenac Sodium68$26,296
Synjardy XrEmpagliflozin/Metformin Hcl28$21,885
JardianceEmpagliflozin33$21,456
LinzessLinaclotide23$13,966
TrulicityDulaglutide12$12,299
EliquisApixaban17$12,077
FarxigaDapagliflozin Propanediol16$11,177
Icosapent Ethyl33$6,167
Cyclosporine16$5,128
VascepaIcosapent Ethyl14$4,699
Metformin Er OsmoticMetformin Hcl16$2,897
Rosuvastatin Calcium75$1,208
Albuterol Sulfate HfaAlbuterol Sulfate41$933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$143$49,13350 claims
Lilly USA, LLCMounjaro, Trulicity$185$46,47442 claims
Boehringer IngelheimSynjardy Xr, Jardiance$24$43,34161 claims
PfizerEliquis$13$12,07717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Porter Ranch

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →